Sars-Cov-2 Virus, Variants B.1.351-B.1.1.7, Spike Protein, Receptor Binding Domain Fusion Heterodimer

3 trials JAnti-infectives

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

1 Sponsors

1 Countries

Phase II/III

Phase II

Phase II/III: 1 Phase II: 2

Sponsors using this IMP

Hipra Scientific S.L. 3

All trials

3 total

A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog… Ended

2023-508458-25-00 Phase II/III 1 country Hipra Scientific S.L.
A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with sea… Ended

2023-506189-29-00 Phase II 1 country Hipra Scientific S.L.
Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coron… Ended

2023-504639-42-00 Phase II 1 country Hipra Scientific S.L.

Showing 1–3 of 3 trials

← All drugs A–Z